These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26779831)

  • 1. Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta.
    Hermanrud C; Ryner M; Luft T; Jensen PE; Ingenhoven K; Rat D; Deisenhammer F; Sørensen PS; Pallardy M; Sikkema D; Bertotti E; Kramer D; Creeke P; Fogdell-Hahn A;
    J Immunol Methods; 2016 Mar; 430():1-9. PubMed ID: 26779831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
    Lam R; Farrell R; Aziz T; Gibbs E; Giovannoni G; Grossberg S; Oger J
    J Immunol Methods; 2008 Jul; 336(2):113-8. PubMed ID: 18511063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point.
    Hermanrud C; Ryner ML; Engdahl E; Fogdell-Hahn A
    J Interferon Cytokine Res; 2014 Jul; 34(7):498-504. PubMed ID: 24444338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
    Cludts I; Meager A; Thorpe R; Wadhwa M
    J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
    Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
    Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
    Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
    Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
    J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.
    Deisenhammer F; Schellekens H; Bertolotto A
    J Neurol; 2004 Jun; 251 Suppl 2():II31-9. PubMed ID: 15264110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-based reporter gene assay for therapy-induced neutralizing antibodies to interferon-beta in multiple sclerosis.
    Martins TB; Rose JW; Gardiner GL; Kusukawa N; Husebye D; Hill HR
    J Interferon Cytokine Res; 2013 Feb; 33(2):52-7. PubMed ID: 23153300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
    Massart C; Gibassier J; Oger J; Le Page E; Edan G
    Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
    Jensen PEH; Warnke C; Ingenhoven K; Piccoli L; Gasis M; Hermanrud C; Fernandez-Rodriguez BM; Ryner M; Kramer D; Link J; Ramanujam R; Auer M; Buck D; Grummel V; Bertotti E; Fissolo N; Oliver-Martos B; Nytrova P; Khalil M; Guger M; Rathmaier S; Sievers-Stober C; Lindberg RLP; Hässler S; Bachelet D; Aktas O; Donnellan N; Lawton A; Hemmer B; Havrdova EK; Kieseier B; Hartung HP; Comabella M; Montalban X; Derfuss T; Sellebjerg F; Dönnes P; Pallardy M; Spindeldreher S; Broët P; Deisenhammer F; Fogdell-Hahn A; Sorensen PS;
    J Neuroimmunol; 2019 Jan; 326():19-27. PubMed ID: 30447419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
    Sominanda A; Lundkvist M; Fogdell-Hahn A; Hemmer B; Hartung HP; Hillert J; Menge T; Kieseier BC
    Arch Neurol; 2010 Sep; 67(9):1095-101. PubMed ID: 20837854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody.
    Liao K; Sikkema D; Wang C; Chen K; DeWall S; Lee TN
    J Immunol Methods; 2012 Jan; 375(1-2):258-63. PubMed ID: 22001556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
    Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
    Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
    Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
    Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.
    Gilli F; Hoffmann F; Sala A; Marnetto F; Caldano M; Valentino P; Kappos L; Bertolotto A; Lindberg RL
    Mult Scler; 2006 Dec; 12(6):738-46. PubMed ID: 17263001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta.
    Kob M; Harvey J; Schautzer F; Kascha S; Bibl D; Egg R; Reindl M; Berger T; Deisenhammer F
    Mult Scler; 2003 Feb; 9(1):32-5. PubMed ID: 12617265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.